Amycon biobank and data registry for amyloidosis
Part of Brain & nervous system, Cancer, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This study collects blood and tissue samples and health data from people with amyloidosis to build a biobank and registry. Researchers hope this will help improve future diagnosis and treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of amyloidosis (suspected or confirmed, any type).
- You must be willing and able to sign a consent form.
- For the sample collection part, you must have newly diagnosed amyloidosis (any type) or relapsed AL amyloidosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects information from people with suspected or confirmed amyloidosis. The goal is to learn more about the condition and improve patient care.
This study collects information from adults with systemic AL amyloidosis to better understand the disease and outcomes. Because it includes pre-treatment records and follows people over time, it may help future patients by improving knowledge of how AL amyloidosis progresses and responds to care.
This study collects information and samples from people newly diagnosed with AL amyloidosis who have not yet received treatment. It aims to improve how this rare disease is diagnosed and managed across Europe.
This study collects health information and, if needed, samples from people diagnosed with certain blood disorders related to plasma cells. Sharing your information may help researchers better understand these diseases and improve future care.
This study creates a registry for people diagnosed with systemic amyloidosis in Hungary. It helps doctors better understand the condition by collecting medical history and tracking outcomes over time.
This trial tests a 5-week cardiac rehabilitation program for people with cardiac amyloidosis (a condition where abnormal protein builds up in the heart). The program aims to improve heart function and quality of life.
Hear when a new Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.